The new staging system for cutaneous melanoma in the era of lymphatic mapping.

Abstract:

:In 2002, the American Joint Committee on Cancer (AJCC) revised the staging system for cutaneous melanoma on the basis of a survival analysis of important melanoma prognostic factors. Features of the revised system include new strata for primary tumor thickness, incorporation of primary tumor ulceration as an important staging criterion in both the tumor (T) and node (N) classifications, revision of the N classification to reflect the prognostic significance of regional nodal tumor burden, and new categories for distant metastatic disease. These changes reflect evolving insight into melanoma arising from the results of numerous clinical investigations and database analyses. One of the most important recent changes in melanoma care is the establishment of lymphatic mapping and sentinel lymph node (SLN) biopsy as a highly accurate and minimally morbid technique for pathologic regional nodal staging. In this article, the salient features of the revised melanoma staging system are examined, with specific attention paid to its use in this era of lymphatic mapping and SLN biopsy.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Rousseau DL Jr,Gershenwald JE

doi

10.1053/j.seminoncol.2004.03.018

subject

Has Abstract

pub_date

2004-06-01 00:00:00

pages

415-25

issue

3

eissn

0093-7754

issn

1532-8708

pii

S0093775404001228

journal_volume

31

pub_type

杂志文章,评审
  • Cancer of the oral cavity and pharynx in young females: increasing incidence, role of human papilloma virus, and lack of survival improvement.

    abstract::From 1975 to the mid 1990s, the incidence of cancer in the oral cavity and pharynx (OC/P) declined substantively, in large part because of successful educational and medical campaigns to reduce cigarette smoking and tobacco chewing. Recent data, however, suggest that the incidence trend in young adults has reversed. T...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2009.07.005

    authors: Bleyer A

    更新日期:2009-10-01 00:00:00

  • Fatigue: definitions, mechanisms, and paradigms for study.

    abstract::Interferon-alpha (IFN-alpha) therapy is frequently associated with significant fatigue, which is often the dominant dose-limiting side effect. The fatigue associated with IFN-alpha therapy is usually dose related, worsens with continued therapy, and is associated with significant depression. Although the direct cause ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Dalakas MC,Mock V,Hawkins MJ

    更新日期:1998-02-01 00:00:00

  • Rituximab plus chemotherapy in follicular and mantle cell lymphomas.

    abstract::Rituximab shows high single-agent activity in both previously untreated and relapsed or refractory indolent non-Hodgkin's lymphoma. In combination with chemotherapy, rituximab has achieved response rates higher than 90% with long duration of remission in phase II studies. Therefore, randomized phase III studies have b...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验,评审

    doi:10.1053/sonc.2003.50024

    authors: Hiddemann W,Dreyling M,Unterhalt M

    更新日期:2003-02-01 00:00:00

  • Neoadjuvant Treatment for Pancreatic Cancer.

    abstract::Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options and exceedingly high mortality rates. Currently, cure can only be achieved through resection, however the vast majority of patients present with advanced disease for which upfront surgery is not an option. In...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2018.12.002

    authors: Raufi AG,Manji GA,Chabot JA,Bates SE

    更新日期:2019-02-01 00:00:00

  • Prostate cancer vaccines: current status.

    abstract::Recent insights into cell-mediated immunotherapy have led to a wave of new trials involving immunotherapy for prostate cancer. Vaccines have evolved from nonspecific immune stimulants like Bacillus Calmette-Guerin (BCG) to much more specific and potent strategies. Techniques currently being investigated include passiv...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Hwang LC,Fein S,Levitsky H,Nelson WG

    更新日期:1999-04-01 00:00:00

  • The use of chemotherapy as palliative treatment for patients with advanced ovarian cancer.

    abstract::Despite the high objective response rate of ovarian cancer to several reported platinum-based combination chemotherapy regimens, the majority of patients with advanced disease ultimately require consideration of a salvage regimen delivered for palliation of symptoms. A number of therapeutic strategies have been used i...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Markman M

    更新日期:1995-04-01 00:00:00

  • Treatment of brain metastases of small cell lung cancer with teniposide.

    abstract::Over 50% of patients with small cell lung cancer (SCLC) will develop symptomatic brain metastases during the course of their disease. Results of whole brain radiotherapy, the standard treatment, are rather poor and relapses are frequent. Thus, new modes of therapy are urgently needed for these patients. In this study,...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Postmus PE,Smit EF,Berendsen HH,Sleijfer DT,Haaxma-Reiche H

    更新日期:1992-04-01 00:00:00

  • Cytotoxic synergy of cisplatin with concurrent hydroxyurea and cytarabine: summary of an in vitro model and initial clinical pilot experience.

    abstract::Cytarabine and hydroxyurea in combination are known to inhibit the DNA excision repair system. Given this system is responsible for repair of cisplatin-DNA adducts, we hypothesized that combining cytarabine, hydroxyurea, and cisplatin in an appropriate schedule might inhibit adduct repair, increase the number of DNA l...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Albain KS,Swinnen LJ,Erickson LC,Stiff PJ,Fisher SG,Fisher RI

    更新日期:1992-06-01 00:00:00

  • Other options in the treatment of advanced breast cancer.

    abstract::Many cytotoxic therapies are available for patients with metastatic breast cancer, but response rates are low and acquired or de novo resistance is virtually universal. Among the agents that are used in the treatment of pretreated metastatic breast cancer are vinorelbine, gemcitabine, nab-paclitaxel, pemetrexed, plati...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2011.04.005

    authors: Cobleigh MA

    更新日期:2011-06-01 00:00:00

  • Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.

    abstract::Relapse following complete remission achieved with a single course of high-dose chemotherapy continues to be the main cause of treatment failure in patients with metastatic breast cancer. A phase I/II trial was initiated that combined the two most active drugs against breast cancer, doxorubicin and paclitaxel (Taxol; ...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Rahman Z,Champlin R,Rondon G,Frye D,Valero V,Mehra R,Hortobagyi G

    更新日期:1997-10-01 00:00:00

  • Future directions in non-small cell lung cancer.

    abstract::Although chemotherapeutic regimens remain limited in activity against non-small cell lung cancer, some novel cytotoxic agents and radiotherapy techniques, alone or in combination, have shown promising advances. Numerous clinical trials have demonstrated increases in overall response rates, and some agents have shown a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Schiller JH

    更新日期:1999-04-01 00:00:00

  • Non-small cell lung cancer treatment-related bone marrow toxicities.

    abstract::A major consequence of administering increasingly aggressive therapies (chemotherapy with or without radiation therapy) in the treatment of non-small cell lung cancer is the adverse effects on the bone marrow that may lead to neutropenia, thrombocytopenia, and/or anemia. Myelosuppression or bone marrow toxicity may al...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.03.014

    authors: Ettinger DS

    更新日期:2005-04-01 00:00:00

  • Lymphoma: diagnosis, staging, natural history, and treatment strategies.

    abstract::Non-Hodgkin's lymphoma (NHL) is not a single disease, but a group of closely related B- and T-cell cancers of the lymphatic system. The incidence of NHL is rising, particularly in the countries of the industrialized world. The increased incidence is poorly understood, but several risk factors have been postulated to b...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2005.01.008

    authors: Zinzani PL

    更新日期:2005-02-01 00:00:00

  • A roundtable discussion on the clinical challenges and options for the treatment of glioblastoma: introducing a novel modality, TTFields.

    abstract::Since its approval in 2011 for patients with recurrent glioblastoma (GBM), physicians have responded positively to the non-invasive nature of the NovoTTF-100A System device (NovoCure Ltd, Haifa, Israel), citing significantly less toxicity and a better quality of life profile compared to available conventional therapie...

    journal_title:Seminars in oncology

    pub_type:

    doi:10.1053/j.seminoncol.2013.10.002

    authors: Butowski N,Wong ET,Mehta MP,Wilson LK

    更新日期:2013-12-01 00:00:00

  • Surgical adjuvant chemotherapy in non-small cell lung cancer.

    abstract::In two different controlled prospective randomized trials the Lung Cancer Study Group has shown that adjuvant CAP chemotherapy is effective in prolonging the disease-free survival. These studies indicate that the adjuvant chemotherapy has its effect by way of diminishing systemic recurrences and that the adjuvant ther...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Holmes EC

    更新日期:1988-06-01 00:00:00

  • Clinicopathologic factors influencing the long-term prognosis following hepatic resection for large hepatocellular carcinoma more than 10 cm in diameter.

    abstract::We resected 158 cases of hepatocellular carcinoma (HCC), including 20 (12.6%) cases of large HCC. These 20 cases were divided into group 1 (curative resection, n = 9) and group 2 (noncurative resection, n = 11). The clinicopathologic features and long-term survival of the cases were evaluated. In groups 1 and 2, porta...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Noguchi T,Kawarada Y,Kitagawa M,Ito F,Sakurai H,Machishi H,Yamagiwa K,Yokoi H,Mizumoto R

    更新日期:1997-04-01 00:00:00

  • Management of side effects in patients with recurrent ovarian cancer.

    abstract::As with many other aspects of health care delivery in the United States, the entrenchment of managed care practices has significantly affected the management of patients with advanced ovarian cancer. Nurses continue to play a vital role in the delivery of health care in this venue, serving as the primary conduit betwe...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Larrison EH

    更新日期:1999-02-01 00:00:00

  • Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer.

    abstract::The purpose of this study was to evaluate the combination of gemcitabine, paclitaxel, and carboplatin in patients with advanced non-small cell lung cancer. Previously untreated patients with stage IIIB or IV non-small cell lung cancer were enrolled into this trial. Sixty-nine patients from the phase II portion and eig...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Burris HA 3rd,Hainsworth JD,Erland JB,Morrissey LH,Kalman LA,Hon JK,Scullin DC Jr,Smith SW,Greco FA

    更新日期:2000-02-01 00:00:00

  • Evaluation of new drugs in small cell lung cancer: the activity of gemcitabine.

    abstract::The evaluation of the activity of new drugs against small cell lung cancer (SCLC) is discussed and the results with gemcitabine are presented. Gemcitabine has activity against untreated SCLC. Preliminary results from an ongoing study also indicate activity in so-called resistant SCLC. ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Postmus PE,Schramel FM,Smit EF

    更新日期:1998-08-01 00:00:00

  • Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials.

    abstract::Recent studies have indicated that bone marrow angiogenesis is increased in multiple myeloma, suggesting that treatment with an antiangiogenic agent might be useful. Among the new antiangiogenic drugs in development, Neovastat (AE-941; Aeterna Laboratories, Quebec City, Canada) can be classified as a naturally occurri...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90035-1

    authors: Falardeau P,Champagne P,Poyet P,Hariton C,Dupont E

    更新日期:2001-12-01 00:00:00

  • Small cell carcinoma of the head and neck: a review.

    abstract::Small cell carcinoma (SCC) has become recognized as a distinct, though relatively infrequent, clinical pathology that occurs in multiple sites throughout the head and neck. Excluding cases that are considered to arise from skin, SCC in the head and neck has been found to develop in nearly all structures associated wit...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.10.024

    authors: Renner G

    更新日期:2007-02-01 00:00:00

  • Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.

    abstract::The approval, in 2015, of the first poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib, Lynparza) for platinum-sensitive relapsed high-grade ovarian cancer with either germline or somatic BRCA1/2 deleterious mutations is changing the way that BRCA1/2 testing services are offered to patients with...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2017.08.004

    authors: Capoluongo E,Ellison G,López-Guerrero JA,Penault-Llorca F,Ligtenberg MJL,Banerjee S,Singer C,Friedman E,Markiefka B,Schirmacher P,Büttner R,van Asperen CJ,Ray-Coquard I,Endris V,Kamel-Reid S,Percival N,Bryce J,Röthlisbe

    更新日期:2017-06-01 00:00:00

  • Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine.

    abstract::Organ function preservation in patients with head and neck cancer can be achieved by intensity-modulated radiation therapy (IMRT). Much of the work on the physics of IMRT has been done for currently available IMRT systems. However, clinical data remain scarce. Before IMRT is accepted as a standard of care, more compre...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,评审

    doi:10.1053/j.seminoncol.2003.11.009

    authors: Chao KS,Ozyigit G,Thorsdad WL

    更新日期:2003-12-01 00:00:00

  • Preclinical experience with docetaxel in gastrointestinal cancers.

    abstract::Docetaxel is a semisynthetic taxane that acts primarily by promoting microtubule assembly and preventing the depolymerization of assembled microtubules, thereby inducing mitotic block and inhibition of cell proliferation. This agent also induces apoptosis and appears to prevent angiogenesis. Although docetaxel has sho...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.04.002

    authors: Bekaii-Saab TS,Villalona-Calero MA

    更新日期:2005-04-01 00:00:00

  • Trans-retinoic acid and related differentiation agents.

    abstract::Interest in retinoids as therapeutic agents has developed as a result of the observations of remission induction with all-trans retinoic acid (tRA) in patients with acute promyelocytic leukemia (APL), and of high objective response rates noted with the combination of cis-retinoic acid (cRA) with interferon-alpha in sq...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Parkinson DR,Smith MA,Cheson BD,Stevenson HC,Friedman MA

    更新日期:1992-12-01 00:00:00

  • Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a phase I study.

    abstract::The goal of this National Cancer Institute-sponsored phase I trial is to determine the feasibility, toxicity, and pharmacokinetics of continuous-infusion (24 hr/d, 7 d/wk, 7 weeks total) intravenous paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) when combined with standard, curative-intent radiation t...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Rosenthal DI,Okani O,Corak J,Kavanaugh D,Kamen B,Vuitch FM,Gazdar AF,Greiner J,Frenkel EF,Carbone DP

    更新日期:1997-08-01 00:00:00

  • Involvement of platelet-derived microparticles in tumor progression and thrombosis.

    abstract::Platelet-derived microparticles (PMPs) represent the most abundant microparticle (MP) subtype. Their presence reflects platelet activity, physiopathology, and the thrombotic state of cancer patients. The quantity and composition of PMPs strictly depends on the way MPs were generated. Because platelets play a key role ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.04.010

    authors: Mezouar S,Mege D,Darbousset R,Farge D,Debourdeau P,Dignat-George F,Panicot-Dubois L,Dubois C

    更新日期:2014-06-01 00:00:00

  • A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: attempts to improve long-term outcome.

    abstract::From February 1985 to June 1993, 173 consecutive, previously untreated patients with small cell lung cancer received individualized treatment tailored to disease extent. Almost all patients (14 of 16) with stage I and II disease and 30 patients with operable stage III disease were submitted to surgery preceded or foll...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Santoro A,Parra HS,Bidoli P,Angelidou M,Cataldo I,Salvini P,Valagussa P,Milani F,Ravasi G,Bonadonna G

    更新日期:1995-02-01 00:00:00

  • Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.

    abstract::To improve the resectability and long-term local control of locally advanced rectal cancer, we have initiated a radiation dose-escalation trial. It is hoped that the radioprotector amifostine will sufficiently reduce rectal morbidity (without also reducing tumor response) to permit increasing radiation doses. Only 6 p...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1053/sonc.2002.37360

    authors: Myerson R,Zobeiri I,Birnbaum E,Dietz D,Fleshman J,Kodner I,Picus J,Ratkin G

    更新日期:2002-12-01 00:00:00

  • Molecular biology of upper gastrointestinal malignancies.

    abstract::While cancers of the upper gastrointestinal tract are related by location, they have distinct clinical and molecular characteristics. This review will focus on the molecular biology of esophageal adenocarcinoma (EAC) of which alterations in p53, overexpression of cyclin D1, loss of p16, and aneuploidy have been best c...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.04.019

    authors: Lin J,Beerm DG

    更新日期:2004-08-01 00:00:00